Abstract:Background Drug safety in children is a major concern; however, there is still a lack of methods for quantitatively measuring, let alone to improving, drug safety in children under different clinical conditions. To assess pediatric drug safety under different clinical conditions, a computational method based on Electronic Medical Record (EMR) datasets was proposed. Methods In this study, a computational method was designed to extract the significant drug-diagnosis associations (based on a Bonferroni-adjusted hypergeometric P-value < 0.05) among drug and diagnosis co-occurrence in EMR datasets. This allows for differences between pediatric and adult drug use to be compared based on different EMR datasets. The drug-diagnosis associations were further used to generate drug clusters under specific clinical conditions using unsupervised clustering. A 5-layer quantitative pediatric drug safety level was proposed based on the drug safety statement of the pediatric labeling of each drug. Therefore, the drug safety levels under different pediatric clinical conditions were calculated. Two EMR datasets from a 1900-bed children's hospital and a 2000-bed general hospital were used to test this method. Results The comparison between the children's hospital and the general hospital showed unique features of pediatric drug use and identified the drug treatment gap between children and adults. In total, 591 drugs were used in the children's hospital; 18 drug clusters that were associated with certain clinical conditions were generated based on our method; and the quantitative drug safety levels of each drug cluster (under different clinical conditions) were calculated, analyzed, and visualized. Conclusion With this method, quantitative drug safety levels under certain clinical conditions in pediatric patients can be evaluated and compared. If there are longitudinal data, improvements can also be measured. This method has the potential to be used in many population-level, health data-based drug safety studies.

On Drug Safety Early Warning Theory

Present situation of drug safety early warning in China and the solution

Exploration of Early-warning for the Safety of Drug Use in Medical Institutions

Build Early-warning System for the Safety of Drug Using in Medical Institutions

Detecting Adverse Drug Event Signals from a Clinical CaseBase.

Analysis on Concept of Drug Safety According to the Result of Systematic Review

A Systematic Review and Qualitative Analysis or the Definition and Scope of Drug Safety in China

Analysis on Concept of Drug Safety According to the Result of Qualitative Interview

Research progress in drug toxicology based on systems biology

A Concise Drug Alerting Rule Set for Chinese Hospitals and Its Application in Computerized Physician Order Entry (CPOE)

Exploratory research on drug safety in China

Thinking of Drug Safety from Risk Society Theory Perspective

Drug Safety Governance: Framework and Development Path

Research progress in adverse drug reaction signal detection methods based on spontaneous reporting system

Broad‐Spectrum Profiling of Drug Safety Via Learning Complex Network

Discussions on the standardized safety evaluation of new drugs in phase I clinical trials

Development Trends of the Post-Marketing Drug Safety Surveillance Systems in EU and US

Predicting the Drug Safety for Traditional Chinese Medicine Through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network.

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Development of the Expert Advisory System in Drug Evaluation

Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data